US · CRVS · BIOTECHNOLOGY
Corvus Pharmaceuticals, Inc. (CRVS) intrinsic value and stock valuation
$9.67as of 2026-11-21 · Mkt cap 1.17B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Corvus Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values CRVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CRVS’s statements →
Corvus Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-42.97M | -$-27.55M | -$-23.41M | -$-32.56M | -$-38.63M |
| Net income | -$-15.28M | -$-62.29M | -$-27.03M | -$-41.31M | -$-43.24M |
| EPSd | -$-191.62K | -$-1.02M | -$-562.77K | -$-887.43K | -$-1.03M |
| Operating cash flow | -$-32.8M | -$-25.42M | -$-23.93M | -$-27.02M | -$-36.72M |
| Capital expenditure | -$-170K | $0.00 | -$-30K | -$-270K | -$-10K |
| Free cash flow | -$-32.97M | -$-25.42M | -$-23.97M | -$-27.29M | -$-36.72M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Total debt | $940K | $1.12M | $1.37M | $2.6M | $3.65M |
| Net debt | -$-3.64M | -$-7.62M | -$-11.25M | -$-10.56M | -$-59.81M |
| Total equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M |
| Cash and short-term investments | $56.8M | $52M | $27.2M | $42.3M | $69.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $100K | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-100K | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $33.7M | $19.4M | $16.5M | $24.5M | $29.1M |
| Selling, general and administrative expenses | $9.25M | $8.16M | $6.88M | $8.1M | $9.52M |
| Other expenses | -$-100K | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $42.9M | $27.6M | $23.4M | $32.6M | $38.6M |
| Cost and expenses | $43M | $27.6M | $23.4M | $32.6M | $38.6M |
| Interest income | $2.5M | $1.82M | $1.58M | $650K | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $10K |
| Depreciation and amortization | $100K | $90K | $150K | $370K | $460K |
| Ebitda | -$-15.18M | -$-62.21M | -$-26.88M | -$-40.94M | -$-42.77M |
| Operating income | -$-42.97M | -$-27.55M | -$-23.41M | -$-32.56M | -$-38.63M |
| Total other income/expenses, net | $27.7M | -$-34.74M | -$-3.62M | -$-8.74M | -$-4.61M |
| Income before tax | -$-15.28M | -$-62.29M | -$-27.03M | -$-41.31M | -$-43.24M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-15.28M | -$-62.29M | -$-27.03M | -$-41.31M | -$-43.24M |
| Weighted average shares outstanding | $79M | $61M | $48M | $46.6M | $41.9M |
| Weighted average diluted shares outstanding | $79.7M | $61M | $48M | $46.6M | $41.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $56.8M | $52M | $27.2M | $42.3M | $69.5M |
| Net receivables | $370K | $220K | $60K | $630K | $540K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $58.2M | $54.4M | $28M | $43.7M | $71.3M |
| Property, plant and equipment, net | $1.06M | $1.33M | $1.39M | $2.57M | $3.64M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $11M | $12.5M | $16.1M | $21.9M | $34.3M |
| Total non-current assets | $12.9M | $14.5M | $17.6M | $24.6M | $38.1M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Accounts payable | $2.49M | $2.58M | $1.52M | $1.98M | $1.56M |
| Short-term debt | $400K | $180K | $1.37M | $1.23M | $1.05M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $9.38M | $35.4M | $6.87M | $10.8M | $9.69M |
| Long-term debt | $530K | $940K | $0.00 | $1.37M | $2.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $530K | $940K | $0.00 | $1.37M | $2.6M |
| Capital lease obligations | $530K | $1.12M | $1.37M | $2.6M | $3.65M |
| Total liabilities | $9.91M | $36.3M | $6.87M | $12.1M | $12.3M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-412.29M | -$-397.01M | -$-334.72M | -$-307.69M | -$-266.38M |
| Accumulated other comprehensive income (loss) | -$-900K | -$-1.29M | -$-970K | -$-560K | $1.87M |
| Total equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M |
| Total investments | $63.2M | $55.8M | $30.7M | $51M | $40.3M |
| Total debt | $940K | $1.12M | $1.37M | $2.6M | $3.65M |
| Net debt | -$-3.64M | -$-7.62M | -$-11.25M | -$-10.56M | -$-59.81M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-15.28M | -$-62.29M | -$-27.03M | -$-41.31M | -$-43.24M |
| Depreciation and amortization | $100K | $90K | $150K | $370K | $460K |
| Stock-based compensation | $5.33M | $3M | $2.15M | $2.69M | $4.23M |
| Change in working capital | $3.58M | -$-1.65M | -$-3.59M | $1.41M | -$-3.24M |
| Accounts receivable | $40K | -$-50K | $560K | -$-80K | -$-510K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-90K | $1.06M | -$-450K | $410K | -$-1.9M |
| Net cash provided by operating activities | -$-32.8M | -$-25.42M | -$-23.93M | -$-27.02M | -$-36.72M |
| Investments in property, plant and equipment | -$-170K | $0.00 | -$-30K | -$-270K | -$-10K |
| Acquisitions, net | $0.00 | $10K | $0.00 | $20K | -$-20K |
| Net cash used for investing activities | -$-7.8M | -$-27.48M | $15.5M | -$-23.28M | $21.6M |
| Common stock issued | $36.4M | $16.4M | $7.84M | $0.00 | $60.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $36.4M | $49M | $7.86M | $0.00 | $62.2M |
| Net change in cash | -$-4.16M | -$-3.88M | -$-540K | -$-50.3M | $47M |
| Cash at end of period | $4.58M | $8.74M | $12.6M | $13.2M | $63.5M |
| Operating cash flow | -$-32.8M | -$-25.42M | -$-23.93M | -$-27.02M | -$-36.72M |
| Capital expenditure | -$-170K | $0.00 | -$-30K | -$-270K | -$-10K |
| Free cash flow | -$-32.97M | -$-25.42M | -$-23.97M | -$-27.29M | -$-36.72M |
Line items
Line items
Line items
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
- CEO
- Richard A. Miller
- Employees
- 37
- Beta
- 0.82
Explore
Frequently asked questions
What is the intrinsic value of Corvus Pharmaceuticals, Inc. (CRVS)?
InvestorsCraft does not currently publish an intrinsic value for CRVS. How the IC value is calculated.
Is CRVS undervalued?
InvestorsCraft does not publish an undervaluation signal for CRVS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.